推薦產品
生物源
mouse
品質等級
100
500
共軛
unconjugated
抗體表格
culture supernatant
抗體產品種類
primary antibodies
無性繁殖
GI191E/A8, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形狀
buffered aqueous solution
物種活性
human
包裝
vial of 0.1 mL concentrate (227M-94)
vial of 0.5 mL concentrate (227M-95)
bottle of 1.0 mL predilute (227M-97)
vial of 1.0 mL concentrate (227M-96)
bottle of 7.0 mL predilute (227M-98)
製造商/商標名
Cell Marque®
技術
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
控制
tonsil
運輸包裝
wet ice
儲存溫度
2-8°C
視覺化
nuclear
基因資訊
human ... BCL6(604)
一般說明
BCL6 is a transcriptional regulator gene that codes for a 706-amino-acid nuclear zinc finger protein. In normal tissue, anti-BCL6 antibody shows strong nuclear staining in a subset of B-lymphocytes, mostly located in germinal centers (GC). BCL6 expression is usually present in follicular lymphomas, diffuse large B-cell lymphomas, and Burkitt lymphomas.
品質
![]() IVD | ![]() IVD | ![]() IVD | ![]() RUO |
聯結
BCL6 Positive Control Slides, Product No. 227S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
準備報告
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他說明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律資訊
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到適合的產品?
試用我們的產品選擇工具.
從最近期的版本中選擇一個:
分析證明 (COA)
Lot/Batch Number
A Dogan et al.
The American journal of surgical pathology, 24(6), 846-852 (2000-06-08)
In this study the authors explored the value of immunostaining for follicular center B-cell markers, BCL-6 and CD10, in paraffin sections as a tool for the differential diagnosis of B-cell lymphomas. The cases studied comprised reactive lymphoid hyperplasia (RLH; n
A Carbone et al.
Blood, 90(6), 2445-2450 (1997-10-06)
The expression pattern of the BCL-6 transcription factor has been assessed in normal and neoplastic B-cell populations and in Hodgkin's disease. However, little is known about BCL-6 expression and its biological significance in T-cell neoplasms. In this study, a series
A Carbone et al.
Blood, 91(3), 747-755 (1998-02-03)
This study was aimed at defining the histogenesis of the pathologic spectrum of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas (AIDS-NHL), including AIDS-related small noncleaved cell lymphoma (AIDS-SNCCL), AIDS-related large noncleaved cell lymphoma (AIDS-LNCCL), AIDS-related large cell immunoblastic lymphoma plasmacytoid (AIDS-IBLP), and
José-Francisco García et al.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 54(1), 31-38 (2005-07-28)
Genetic immunization can be combined with hybridoma technology to generate high-affinity monoclonal antibodies (MAbs). A new anti-BCL-6 MAb (GI191E/A8) was produced by cloning full-length BCL-6 cDNA into a eukaryotic vector and delivering this into mouse epidermis using a helium gene
Antonino Carbone et al.
Human pathology, 41(5), 621-631 (2010-04-20)
Published in September 2008, the updated World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues introduces provisional borderline categories for lymphoma cases that demonstrate overlapping clinical, morphological, and/or immunophenotypic features between well-established entities. These overlapping features pose real
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務